QuantHealth Raises $45M Series B
QuantHealth, based in Tel Aviv, a developer of an AI-driven simulation platform for clinical trial design, has secured $45 million in Series B funding. This round brings the company's total funding to approximately $70 million.
The funding round was led by Qumra Capital, with participation from Pitango HealthTech, Sanofi Ventures, Artofin Venture Capital Fund L.P., Bertelsmann Healthcare Investments (BHI), GC Ventures, NewHealth Ventures, Shoni Top Ventures and Esplanade Ventures.
QuantHealth plans to use the new capital to advance its research and development capabilities, grow its team, and expand its product portfolio into the broader drug development process, including treatment positioning and go-to-market strategies.
Founded in 2020 by CEO Orr Inbar, QuantHealth provides an AI-powered platform that simulates patient-level biology to predict clinical trial responses. The company aims to identify success factors and potential safety or efficacy issues before trials begin, helping to reduce failure rates in drug development.
Funding Details
Company Website: https://quanthealth.ai
Company: QuantHealth
Raised: $45M
Round: Series B
Funding Date: August 4, 2026
Lead Investor: Qumra Capital
Additional Investors: Pitango HealthTech, Sanofi Ventures, Artofin Venture Capital Fund L.P., Bertelsmann Healthcare Investments (BHI), GC Ventures, NewHealth Ventures, Shoni Top Ventures, Esplanade Ventures
Software Category: Health Tech